Primary effects of intravitreal bevacizumab inpatients with diabetic macular edema

20137 citationsJournal Articlegold Open Access

Authors

Primary IVB at a dose of 1.25 mg on monthly interval seems to provide stability and improvement in BCVA and CMT in patient with DME.

Good health and well-being

Published in: Pakistan Journal of Medical Sciences

Volume 29, Issue 4, pp. 1018-22

Field-Weighted Citation Impact: 0.57